Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy
You can choose the best time of day to inject BPC 157 that suits your schedule
Studies examine effects on tissue repair and healing processes
AOD-9604 is not approved by the FDA for therapeutic or cosmetic use
US$ 27.92
US$ 25.12
US$ 25.50
